Attached files

file filename
EX-99 - FLUOROPHARMA MEDICAL, INC.ex99-06152012_010654.htm
EX-17 - FLUOROPHARMA MEDICAL, INC.ex17-06152012_010652.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 12, 2012

 

FluoroPharma Medical, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Nevada

 

333-151381

 

20-8325616

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number) 

 

(IRS Employer Identification No.)  


8 Hillside Avenue, Suite 207

 

 

Montclair, NJ

 

07042

(Address of Principal Executive Offices) 

 

(Zip Code)

 

Registrant's telephone number, including area code: (973) 744-1565

 

(Former name or former address, if changed since last report)

                                                       

Copies to:

Marc J. Ross, Esq.

Marcelle S. Balcombe, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Phone: (212) 930-9700

Fax: (212) 930-9725

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[   ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

 

[   ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

 

[   ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[   ]

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)






Item 5.02 Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On June 14, 2012, Johan M. (Thijs) Spoor, the current President and CEO of FluoroPharma Medical, Inc. (the Company) was appointed as Chairman of the Board of Directors of the Company.


On June 12, 2012, Dr. David Elmaleh resigned his positions as Chairman of the Board and as a director of FluoroPharma Medical, Inc. (the Company), effective on the same day. A copy of Dr. Elmalehs resignation letter is attached hereto as Exhibit 17.1.  


On June 15, 2012, the Company provided Dr. Elmaleh with a copy of the disclosures it is making in response to Item 5.02 on this Form 8-K, and provided Dr. Elmaleh the opportunity to furnish it with a letter stating whether he agrees with the above statements pertaining to his resignation and if not, the respects in which he does or does not agree.  


Item 9.01 Financial Statements and Exhibits.


Exhibit

Description

17.1

Letter of Resignation from Dr. Elmaleh dated June 12, 2012

99.1

Press Release issued June 15, 2012






 

 




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

 

 

FluoroPharma Medical, Inc.



 

Dated: June 15, 2012

By:/s/ Johan M. Thijs Spoor

 

 

Johan M. (Thijs) Spoor

CEO, President and CFO